Background: A proportion of patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) have poor survival, and currently no standard treatment is available, which poses a great challenge to physicians. This study aimed to assess and compare the efficacy and safety of the combination of brachytherapy with iodine-125 seeds and systemic chemotherapy versus systemic chemotherapy alone for synchronous extracranial oligometastatic NSCLC.
Materials And Methods: After a systematic retrospective review of the case database between 1st Mar 2014 and 30th Mar 2018, data were obtained on 69 NSCLC patients with extracranial oligometastatic NSCLC. Among them, 32 patients received brachytherapy with iodine-125 seeds combined with systemic chemotherapy (group A), and the remaining 37 patients received chemotherapy alone (group B). The primary endpoint was overall survival (OS), and the secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and complications.
Results: The demographic and clinical characteristics were not significantly different between the groups (all >0.05). The overall 3-month ORR was significantly higher in group A (65.6% vs 37.8%, =0.030) than in group B. With a median follow-up time of 23 months, the PFS and OS were 11.6 (95% CI: 7.0-16.2) months vs 6.3 (95% CI: 3.4-9.2) months (=0.036) and 17.6 (95% CI: 13.9-21.3) months vs 11.2 (95% CI: 7.7-14.7) months (=0.042) in groups A and B, respectively. Furthermore, in Cox regression analysis, local brachytherapy was an independent prognostic factor for both PFS (HR=0.416, 95% CI: 0.246-0.702, =0.001) and OS (HR=0.375, 95% CI: 0.216-0.653, =0.001). Severe complications were not observed in either of the groups.
Conclusion: The combination of brachytherapy with iodine-125 seeds and systemic chemotherapy is superior to chemotherapy alone for synchronous extracranial oligometastatic NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494957 | PMC |
| http://dx.doi.org/10.2147/CMAR.S267694 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.
PLoS One
January 2025
Department of Laboratory, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R. China.
Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.
View Article and Find Full Text PDFAucubin Promotes BMSCs Proliferation and Differentiation of Postmenopausal Osteoporosis Patients by Regulating Ferroptosis and BMP2 Signalling.
J Cell Mol Med
January 2025
Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Postmenopausal osteoporosis (PMOP) is a chronic systemic bone metabolism disorder. Promotion in the patterns of human bone marrow mesenchymal stem cells (hBMSCs) differentiation towards osteoblasts contributes to alleviating osteoporosis. Aucubin, a natural compound isolated from the well-known herbal medicine Eucommia, was previously shown to possess various pharmacological effects.
View Article and Find Full Text PDFGender Differences in Blood Pressure Control Among Hypertensive Patients: A Cross-Sectional Study at a Tertiary Hospital.
J Clin Hypertens (Greenwich)
January 2025
Faculty of Medicine, University of Jordan, Amman, Jordan.
Our study aims to assess gender differences in blood pressure (BP) control among hypertensive patients in Jordan and identify factors influencing these differences. We conducted a cross-sectional study at Jordan University Hospital (JUH), collecting data from 601 hypertensive patients following up in JUH clinics. Patients were eligible if they were >18 years old, diagnosed with hypertension, taking anti-hypertensive medication for at least 6 months, and had no chronic kidney disease.
View Article and Find Full Text PDFComprehensive treatment focusing on transarterial chemoembolization for postoperative liver metastasis in gastric cancer patients.
Am J Transl Res
December 2024
Department of Gastric Tumor Surgery, Gansu Provincial Cancer Hospital No. 2 Xiaoxihu East Street, Qilihe District, Lanzhou 730050, Gansu, China.
Objective: To investigate the clinical efficacy of comprehensive treatment focusing on transarterial chemoembolization (TACE) for postoperative liver metastasis in patients with gastric cancer and analyze the factors influencing prognosis.
Methods: A retrospective study was conducted on 116 patients who developed liver metastasis after gastric cancer surgery and were admitted to Gansu Provincial Cancer Hospital between January 2018 and February 2020. The observation group, consisting of 62 patients, received TACE with fluorouracil (FU) + irinotecan (CPT-11) + oxaliplatin (OXA) and moderate lipiodol embolization.
Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.
Cureus
December 2024
Department of Pediatrics, Toranomon Hospital, Tokyo, JPN.
Background: Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.
Materials And Methods: Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!